CMS Innovation Grants Seek New Payment Models
This article was originally published in The Gray Sheet
The agency plans to award up to $1 billion toward projects evaluating new payment and delivery models in various health care contexts, including models targeting particular clinical specialties, such as oncology and cardiology.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.